Logo

Effective and Rapid Osteoclast Inhibition by Denosumab, is Reflected in Serum C Telopeptide (CTX), Across Different Tumor Types

Authors

  • S. Tuyls

    Depts. of Medical Oncology, Regional Hospital Sint Maria, Ziekenhuislaan 100, 1500 Halle, Belgium

  • F. Geurs

    Depts. of Medical Oncology, Regional Hospital Sint Maria, Ziekenhuislaan 100, 1500 Halle, Belgium

  • Y. Deprest

    Laboratory, Regional Hospital Sint Maria, Ziekenhuislaan 100, 1500 Halle, Belgium

DOI:

https://doi.org/10.6000/1927-7229.2013.02.02.1

Keywords:

Bone metastases, denosumab, serum c telopeptide.

Abstract

Denosumab, a monoclonal antibody against RANKL has superior efficacy against bone metastases. Its in vivo activity can be measured recently by dosing of serum C telopeptide, produced by collagen destruction by the osteoclast. We report the first patient series, across several tumor types of the efficacy of denosumab in normalising serum CTX.

References

Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012; [Epub ahead of print]. http://dx.doi.org/10.1093/annonc/mds175

Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379(9810): 39-46. http://dx.doi.org/10.1016/S0140-6736(11)61226-9

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28(35): 5132-39. http://dx.doi.org/10.1200/JCO.2010.29.7101

Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12(4): 1221-28. http://dx.doi.org/10.1158/1078-0432.CCR-05-1933

Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97 (3 Suppl): 887-92. http://dx.doi.org/10.1002/cncr.11138

Clemons M, Gelmo, KA, Pritchard KI, Paterson AH. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol 2012; 19(5): 259-68. http://dx.doi.org/10.3747/co.19.1011

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97(1): 59-69. http://dx.doi.org/10.1093/jnci/dji002

Brown-Glaberman U, Stopeck AT. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012; 6: 89-99.

Dekoninck J, Geurs F, Deloecker R, Deprest Y. Significant pain relief with loading dose zoledronic acid in bone metastases is only seen in patients with elevated initial serum C telopeptide (CTX). Pragm Observ Res 2011; 2: 1-6.

Downloads

Published

2013-04-03

Issue

Vol. 2 No. 2 (2013)

Section

Articles

How to Cite

Effective and Rapid Osteoclast Inhibition by Denosumab, is Reflected in Serum C Telopeptide (CTX), Across Different Tumor Types. (2013). Journal of Analytical Oncology, 2(2),  58-61. https://doi.org/10.6000/1927-7229.2013.02.02.1

Similar Articles

41-42 of 42

You may also start an advanced similarity search for this article.